Intra-cellular Therapies, Inc. logo

Intra-cellular Therapies, Inc. Share Price (NASDAQ: ITCI)

▲

-131.92

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 1 Apr 2025

Check the interactive Intra-cellular Therapies, Inc. Stock chart to analyse performance

Intra-cellular Therapies, Inc. Key Stats

Check Intra-cellular Therapies, Inc. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$131.92
Open
$131.9
Market Capitalization
$14.1B
Today's Volume
$3.0M
Revenue TTM
$680.9M
EBITDA
$-116.2M
Earnings Per Share (EPS)
$-0.73
Profit Margin
-10.97%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-8.58%

Global Institutional Holdings in Intra-cellular Therapies, Inc.

  • Name

    Holdings %

  • FMR Inc

    10.42%

  • Vanguard Group Inc

    9.14%

  • BlackRock Inc

    5.75%

  • JPMorgan Chase & Co

    4.82%

  • Wasatch Advisors LP

    3.06%

  • NORGES BANK

    3.02%

Analyst Recommendation on Intra-cellular Therapies, Inc. Stock

Rating
Trend

Buy

    86%Buy

    13%Hold

    0%Sell

Based on 23 Wall street analysts offering stock ratings for Intra-cellular Therapies, Inc.(by analysts ranked 0 to 5 stars)

About Intra-cellular Therapies, Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder. In addition, the company develops lenrispodun (ITI-214) in Phase 2 clinical trial for the treatment of Parkinson's disease; ITI-1284-ODT-SL in Phase 2 trial for the treatment of generalized anxiety disorder, and psychosis and agitation in patients with Alzheimer's disease; ITI-1020 in Phase 1 trial for cancer immunotherapy; and ITI-1549 in preclinical studies for mood and anxiety disorders. It distributes its products through third-party wholesale drug distributors. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in Bedminster, New Jersey.
Organization
Intra-cellular Therapies, Inc.
Employees
860
CEO
Dr. Sharon Mates Ph.D.
Industry
Health Technology

Key Management of Intra-cellular Therapies, Inc.

NameTitle
Dr. Sharon Mates Ph.D.
Co-Founder, Chairman & CEO
Mr. Michael I. Halstead J.D.
President
Mr. Sanjeev Narula
Executive VP, CFO & Treasurer
Dr. Suresh K. Durgam M.D.
Executive VP & Chief Medical Officer
Mr. Mark Neumann
EVP & Chief Commercial Officer
Dr. Robert E. Davis Ph.D.
Senior VP & Chief Scientific Officer
Mr. Juan Fernando Sanchez M.D.
Vice President of Corporate Communications & Investor Relations
Ms. Karen Patruno Sheehy Esq.
Senior VP & Chief Compliance Officer
John P. Condon
Senior VP, General Counsel & Secretary
Dr. Michael Olchaskey Pharm.D.
Senior VP & Head of Regulatory Affairs

Important FAQs about investing in ITCI Stock from India :

What is Intra-cellular Therapies, Inc. share price today?

Intra-cellular Therapies, Inc. share price today is as on at the close of the market. Intra-cellular Therapies, Inc. share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Intra-cellular Therapies, Inc. share?

Intra-cellular Therapies, Inc. share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Intra-cellular Therapies, Inc. stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Intra-cellular Therapies, Inc. Stock (ITCI) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Intra-cellular Therapies, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Intra-cellular Therapies, Inc. Shares .

What is the minimum amount required to buy Intra-cellular Therapies, Inc. Stock (ITCI) from India?

Indian investors can start investing in Intra-cellular Therapies, Inc. (ITCI) shares with as little as ₹90.69 or $1 (as of February 14, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹906.90 in Intra-cellular Therapies, Inc. stock (as per the Rupee-Dollar exchange rate as on February 14, 2026). Learn more about fractional shares .

What are the returns that Intra-cellular Therapies, Inc. has given to Indian investors in the last 5 years?

Intra-cellular Therapies, Inc. stock has given 0.0% share price returns and 24.88% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?